Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
PaperCitations, authors & open-access status
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2,762 citations, 1998 year and closed oa status.
2,762
Citations
1998
Year
closed
OA Status